NCT06211088View on ClinicalTrials.gov

Famotidine Versus Placebo in Emergency Pediatric Surgery As a Risk to Postoperative Nausea and Vomiting

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

December 30, 2024

Study Completion Date

January 30, 2025

Conditions
Postoperative Nausea and Vomiting
Interventions
DRUG

famotidine plus10ml normal saline

to evaluate the difference of the gastric volume by quantitative measurements of gastric antrum preoperatively and postoperatively by using 5mg famotidine

OTHER

10ml normal saline

to evaluate the difference of the gastric volume by quantitative measurements of gastric antrum preoperatively and postoperatively by placebo

Trial Locations (1)

Unknown

Zaher, Cairo

All Listed Sponsors
lead

Aswan University Hospital

OTHER

NCT06211088 - Famotidine Versus Placebo in Emergency Pediatric Surgery As a Risk to Postoperative Nausea and Vomiting | Biotech Hunter | Biotech Hunter